PuraPharm Corporation Limited provided earnings guidance for the year ended December 31, 2018. For the year, the company is expected that the Group's revenue will record an increase of more than 20% as compared with the corresponding period of the previous year. The profit for the year ended 31 December 2018 will also record a substantial increase as compared with the corresponding period in 2017, the Group is expected to record a net profit of more than HKD 15 million for the year ended 31 December 2018. The increase in revenue was mainly attributable to (i) an increase in sales of the Group's China Concentrated Chinese Medicine Granules segment resulted from the increase in sales quantity to the Group's distributors. During the year ended 31 December 2018, the Group continued to devote more selling and distribution expenses to strengthen the promotion of the Group's products and brands in China, as a result, more new customers were developed and the sales to the Group's existing customers continued to grow (ii) the results of the newly acquired subsidiaries in 2017 were fully consolidated in the Group's result for the year ended 31 December 2018, whereas only a few months' results since the completion of acquisitions were consolidated in the Group's result for the corresponding period in 2017. The increase in profit was primarily attributable to (i) an increase in fair value gain on the Group's biological assets as compared to the corresponding period in 2017 based on a valuation of the biological assets as of 31 December 2018, and (ii) an increase in the profit contribution from China CCMG segment as compared to the corresponding period in 2017, and (iii) profits contributed by the newly acquired subsidiaries in 2017.